Vivek Ramaswamy speaking at the NRA-ILA Leadership Forum (Jeremy Hogan/Sipa USA/Sipa via AP Images)

May 3, 2023 10:00 AM EDT

Vivek Ramaswamy is running an anti-“woke,” anti-China presidential campaign. It's a contrast to his time as CEO

Max Gelman

Senior Editor

WOLFEBORO, NH — Biotech entrepreneur Vivek Ramaswamy is running for president as an anti-ESG and China hawk, two themes he’s deployed early and often during his fledgling campaign to win over Republican primary voters.

But his positions as a candidate differ, sometimes substantially, from his stances just a few years ago, when he was CEO of the biotech company Roivant Sciences — a career that has contributed to the personal wealth he’s using to bankroll his campaign.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Vivek Ramaswamy is running an anti-“woke,” anti-China presidential campaign. It's a contrast to his time as CEO

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence

Vivek Ra­maswamy is run­ning an an­ti-“woke,” an­ti-Chi­na pres­i­den­tial cam­paign. It's a con­trast to his time as CEO

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

FDA ap­proves ma­jor de­pres­sive drug af­ter re­ject­ing it mul­ti­ple times in past two decades

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

Vivek Ramaswamy is running an anti-“woke,” anti-China presidential campaign. It's a contrast to his time as CEO

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence